Post-mortem Studies of Dopaminergic Function in Schizophrenia

  • A. J. Cross
  • T. J. Crow
  • F. Owen
Part of the Satellite Symposia of the IUPHAR 9th International Congress of Pharmacology book series (SSNIC)

Abstract

Since its inception in 1965 (Randrup & Munkvad 1965), the dopamine hypothesis of schizophrenia has been extremely rewarding in terms of generating investigation. In its simplest form the hypothesis proposes that an increase in brain dopaminergic function may be responsible for the production of some of the symptoms of schizophrenia. Two major lines of evidence support the hypothesis. Firstly the dopamine receptor antagonism displayed by neuroleptics correlates with, and may be the only pre-requisite for their anti-psychotic action (Creese et al 1976, Seeman et al 1976, Johnstone et al 1978). Secondly, dopamine-potentiating drugs such as amphetamine can induce a schizophrenia-like paranoid state in non-psyohotic individuals, and worsen the pre-existing psychosis of schizophrenia (Connell 1958, Angrist et al 1974).

Keywords

HPLC Dopamine Dementia Schizophrenia Choline 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Angrist, B., Lee, H.K. and Gershon, S. (1974) The antagonism of amphetamine induced symptomatology by a neuroleptic. Amer. J. Psychiat., 131, 817–819.Google Scholar
  2. Bacopoulos, N.C., Spokes, E.G., Bird, E.D. and Roth, R.H. (1979) Antipsychotic drug action in schizophrenic patients: effect on cortical dopamine metabolism after long-term treatment. Science, 205, 1405–1407.PubMedCrossRefGoogle Scholar
  3. Bird, E.D., Spokes, E.G., Barnes, J., Mackay, A.V.P., Iversen, L.L. and Shepherd, M. (1977) Increased brain dopamine and reduced glutamic acid decarboxylase and choline acetyltransferase activity in schizophrenia and related psychoses. Lancet, ii, 1157–1159.CrossRefGoogle Scholar
  4. Bird, E.D., Crow, T.J., Iversen, L.L., Longden, A., Mackay, A.V.P., Riley, G.J. and Spokes, E.G. (1979) Dopamine and homovanillic acid concentrations in post-mortem brain in schizophrenia. J. Physiol., 293, 36–37.Google Scholar
  5. Bokobza, B., Ruberg, M., Scatton, B., Javoy-Agid, F. and Agid, Y. (1984) 3H-spiperone binding, dopamine and HVA concentrations in Parkinsons disease and supranuclear palsy. Eur. J. Pharmacol., 99, 167–175.PubMedCrossRefGoogle Scholar
  6. Bowers, M.B. (1974) Central dopamine turnover in schizophrenic syndromes. Arch. Gen. Psychiat., 31, 50–54.PubMedCrossRefGoogle Scholar
  7. Conncell, P.H. (1958) Amphetamine psychosis. London: Chapman and Hall (for the Institute of Psychiatry).Google Scholar
  8. Creese, I., Burt, D.R. and Snyder, S.H. (1976) Dopamine receptor binding predicts clinical and pharmacological potencies of anti-schizophrenic drugs. Science, 192, 481–483.PubMedCrossRefGoogle Scholar
  9. Cross, A.J., Crow, T.J. and Owen, F. (1981) 3H-flupenthixol binding in the brains of schizophrenics: evidence for a selective increase of dopamine D2 receptors. Psychopharmacol., 74, 122–124.CrossRefGoogle Scholar
  10. Cross, A.J. and Joseph, M.H. (1981) The concurrent estimation of the major monoamine metabolites in human and non-human primate brain by HPLC with fluorescence and electrochemical detection. Life Sci., 28, 499–505.PubMedCrossRefGoogle Scholar
  11. Cross, A.J. and Rossor, M. (1983) Dopamine D1 and D2 receptors in Huntington’s Disease. European J. Pharmacol., 88, 223–229.CrossRefGoogle Scholar
  12. Crow, T.J. (1980) Molecular pathology of schizophrenia: more than one disease process? Brit. Med. J., 280, 66–68.PubMedPubMedCentralCrossRefGoogle Scholar
  13. Crow, T.J., Deakin, J.F.W., Johnstone, E.C. and Longden, A. (1976) Dopamine and schizophrenia. Lancet, 2, 563–566.PubMedCrossRefGoogle Scholar
  14. Crow, T.J., Baker, H.F., Cross, A.J., Joseph, M.H., Lofthouse, R., Longden, A., Owen, F. and Riley, G.J., Glover, V., Killpack, W.S. and Dahlstrom, A. (1978) Monoamines in chronic schizophrenia. British Journal of Psychiatry, 134, 249–256.CrossRefGoogle Scholar
  15. Crow, T.J., Owens, D.G.C., Johnstone, E.C., Cross, A.J. and Owen, F. (1983) Does tardive dyskinesia exist? Modern Problems of Pharmacopsychiatry, 21, 206–219.PubMedCrossRefGoogle Scholar
  16. Farley, I.J., Price, K.S. and Hornykiewicz, O. (1977) Dopamine in the limbic regions of human brain:- normal and abnormal. Adv. Biochem. Psychopharmacol., 16, 57–64.PubMedGoogle Scholar
  17. Ferrier, I.N., Johnstone, E.C. and Crow, T.J. Clinical and hormonal effects of apomorphine in schizophrenia II. Hormonal effects (in preparation).Google Scholar
  18. Johnstone, E.C., Crow, T.J., Frith, C.D., Carney, M.W.P. and Price, J.S. (1978) Mechanism of the antipsychotic effect in the treatment of acute schizophrenia. Lancet, i, 848–851.CrossRefGoogle Scholar
  19. Krawiecka, M., Goldberg, D. and Vaughan, M. (1977) A standardised psychiatric assessment for rating chronic psychotic patients. Acta Psychiatrica Scandinavica 55, 299–308.PubMedCrossRefGoogle Scholar
  20. Lee, T., Seeman, P., Tourtellotte, W.W., Farley, I.J. and Hornykiewicz, O. (1978) Binding of 3H-neuroleptics and 3H-apomorphine in schizophrenic brain. Nature, 274, 897–900.PubMedCrossRefGoogle Scholar
  21. Mackay, A.V.P., Iversen, L.L., Rossor, M., Spokes, E., Arregui, A., Creese, I. and Snyder, S.H. (1982) Increased brain dopamine and dopamine receptors in schizophrenia. Arch. Gen. Psychiat., 39, 991–997.PubMedCrossRefGoogle Scholar
  22. Muller, P. and Seeman, P. (1978) Dopaminergic supersensitivity after neuroleptics: time course and specificity. Psychopharmacol., 60, 1–11.CrossRefGoogle Scholar
  23. Owen, F., Cross, A.J., Crow, T.J., Longden, A., Poulter, M. and Riley, G.J. (1978) Increased dopamine-receptor sensitivity in schizophrenia. Lancet, ii, 223–226.CrossRefGoogle Scholar
  24. Owen, F., Cross, A.J., Waddington, J.L., Poulter, M., Gamble, S.J. and Crow, T.J. (1980) Dopamine-mediated behaviour and 3H-spiperone binding to striatal membranes in rats after nine months haloperidol administration. Life Sciences, 26, 55–59.PubMedCrossRefGoogle Scholar
  25. Owen, F., Cross, A.J., Crow, T.J., Poulter, M. and Waddington, J.L. (1982) Dopamine D2 receptor increases in schizophrenic brains: effect of neuroleptics and relationship to symptomatology. Brit. J. Psychiat., 140, 205.Google Scholar
  26. Owen, F., Cross, A.J. and Crow, T.J. (1983) Ligand binding studies in schizophrenia. In Cell Surface Receptors. (ed. P.G. Strange). Cambridge University Press, pp 163–183.Google Scholar
  27. Owens, D.G.C., Johnstone, E.C. and Frith, C.D. (1982) Spontaneous involuntary disorders of movement in neuroleptic treated and untreated chronic schizophrenics — prevalence, severity and distributions. Arch. Gen. Psychiat., 39, 452–461.PubMedCrossRefGoogle Scholar
  28. Post, R.M., Fink, E., Carpenter, W.T. and Goodwin, F.K. (1975) Cerebrospinal fluid amine metabolites in acute schizophrenia. Arch. Gen. Psychiat., 32, 1013–1069.CrossRefGoogle Scholar
  29. Randrup, A. and Munkvad, I. (1965) Special antagonism of amphetamine-induced abnormal behaviour. Inhibition or stereotyped activity with increase of some normal activities. Psychopharmacologia, 7, 416–422.PubMedCrossRefGoogle Scholar
  30. Reisine, T.D., Rossor, M., Spokes, E., Iversen, L.L. and Yamamura, H.I. (1980) Opiate and neuroleptic receptor alterations in human schizophrenic brain tissue. In Receptors for Neurotransmisters and Peptide Hormones. (eds. G. Pepeu, M.J. Kuhar and S.J. Enna). Raven Press, New York, pp 443–450.Google Scholar
  31. Reynolds, G.P. (1983) Increased concentration and lateral asymmetry of amygdala dopamine in schizophrenia.Google Scholar
  32. Rinne, U.K. (1982) Brain dopamine receptors in Parkinsons disease. In Movement Disorders. (eds. C.D. Marsden and S. Fahn). Butterworth, London, pp 59–74.Google Scholar
  33. Seeman, P., Lee, T., Chau-Wong, M. and Wong, K. (1976) Antipsychotic drug doses and neuroleptic/dopamine receptors. Nature (London), 261, 717–719.CrossRefGoogle Scholar

Copyright information

© The Contributors 1986

Authors and Affiliations

  • A. J. Cross
  • T. J. Crow
  • F. Owen

There are no affiliations available

Personalised recommendations